Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | FPR2 | P25090 | 7/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20334999 | 0.86 | KMT2A (0.74) | KMT2AFPR2NAALAD2FOLH1 | |
| SCHEMBL20334998 | 0.86 | KMT2A (0.74) | KMT2AFPR2NAALAD2FOLH1 | |
| SCHEMBL4887449 | 0.85 | FOLH1 (0.48) | FPR2NPSR1FOLH1SMN1; SMN2MAPK1 | |
| SCHEMBL4887439 | 0.85 | FOLH1 (0.48) | FPR2NPSR1FOLH1SMN1; SMN2MAPK1 | |
| SCHEMBL4505211 | 0.76 | GAA (0.55) | KMT2ANPSR1MAPTUSP30 | |
| SCHEMBL2722853 | 0.76 | ALDH1A1 (0.58) | KMT2ANAALAD2MAPTFOLH1 | |
| SCHEMBL6249941 | 0.75 | KMT2A (0.58) | KMT2ANAALAD2 | |
| SCHEMBL236527 | 0.75 | KMT2A (0.58) | KMT2ANAALAD2 | |
| SCHEMBL6249937 | 0.75 | KMT2A (0.58) | KMT2ANAALAD2 | |
| SCHEMBL236526 | 0.75 | KMT2A (0.58) | KMT2ANAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632420-B1 | GLUTAMINE DERIVATIVES AS DEODORANTS | GIVAUDAN SA (CH) | 2017-01-04 | — | — | EP | disclosed |
| US-9198845-B2 | Glutamine derivatives as deodorants | GIVAUDAN S.A. (CH) | 2015-12-01 | — | — | US | disclosed |
| US-9198845-B2 | Glutamine derivatives as deodorants | GIVAUDAN S.A. (CH) | 2015-12-01 | — | — | US | disclosed |
| US-20140147403-A1 | GLUTAMINE DERIVATIVES AS DEODORANTS | Givaudan, S.A. (CH) | 2014-05-29 | — | — | US | disclosed |
| US-20140147403-A1 | GLUTAMINE DERIVATIVES AS DEODORANTS | Givaudan, S.A. (CH) | 2014-05-29 | — | — | US | disclosed |
| EP-2632420-A1 | GLUTAMINE DERIVATIVES AS DEODORANTS | Givaudan SA (CH) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012056014-A1 | GLUTAMINE DERIVATIVES AS DEODORANTS | GIVAUDAN SA (CH) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140147403-A1 | GLUTAMINE DERIVATIVES AS DEODORANTS | GLUL, QARS1, TYR | KMT2A 2464/4885FPR2 2008/4885NPSR1 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.